Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 3, Issue 2, Apr-Jun, 2026
Page No.: 31-44

Review

Network Pharmacology in Modern Drug Discovery and Development

Dikshya Patjoshi[1], Ayushi Sharma[2], Tannya Singh[3], Aakriti Shah[4], Farah Deeba[5*]

[1-4] 4th year B.Pharm, School of Pharmacy, Sharda University, Greater Noida

[5]Assistant Professor, School of Pharmacy, Sharda University, Greater Noida

Corresponding Author:
Dr. Farah Deeba

Email:
farah.deeba@sharda.ac.in

DOI:
10.62896/cplr.3.2.06

Conflict of interest: *NIL*

Article History
Received: 12/03/2026
Accepted: 20/05/2026
Published: 27/05/2026

Abstract:
The "one drug, one target, one disease" philosophy has traditionally dominated the process of drug discovery. Successful in instances of cancers, Alzheimer's, diabetes, and cardiovascular diseases, it has fallen short for multifactorial diseases with multiple molecular pathways and biological networks being involved simultaneously. Network pharmacology has been a pioneering strategy that marries systems biology, computational models, bioinformatics, and multi-omics tools to study drug–target–disease interactions from a comprehensive outlook. By moving from single-target therapy to multi-target and multi-pathway modulation, it sheds new light on disease mechanisms as well as therapeutic interventions. Network pharmacology is critical to target identification, drug repurposing, and rational multi-target drug design, greatly facilitating the process of drug discovery while containing costs. Coupling with artificial intelligence, pharmacogenomics, and big data analytics further strengthens its predictive ability and clinical utility. It is also helpful in validating natural products, traditional medicines, and combination therapies through network-based systems. In spite of challenges like data quality, complexity of the network, and translational gaps, network pharmacology is a paradigm shift in contemporary drug discovery and personalized medicine, promising safer, more effective, and patient-specific therapeutic approaches.

Keywords: Network pharmacology, drug discovery, drug repurposing, multi-target drug design, pharmacogenomics, AI in pharmacology, systems biology, precision medicine

Introduction

Drug discovery and development have traditionally followed the “one drug, one target, one disease” paradigm, where a single therapeutic agent is designed to act on a specific molecular target to alleviate or cure a disease. While this approach has produced numerous successful drugs, it has significant limitations when addressing complex, multifactorial diseases such as cancer, Alzheimer’s disease, diabetes, cardiovascular disorders, and autoimmune conditions. These diseases are rarely driven by a single genetic or molecular abnormality but rather arise from intricate interactions among genes, proteins, metabolites, and signaling pathways within biological systems. As a result, single-target therapies often fail to achieve the desired efficacy or lead to unforeseen side effects[1].

To overcome these challenges, the field of network pharmacology has emerged as a transformative approach in modern drug discovery. Coined by Andrew L. Hopkins in 2007, network pharmacology integrates systems biology, computational biology, bioinformatics, and multi-omics data to analyze the complex relationships among drugs, targets, diseases, and biological pathways. Unlike reductionist strategies, network pharmacology

Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 3, Issue 2, Apr-Jun, 2026
Page No.: 31-44

adopts a holistic, systems-level perspective, aiming to understand how drugs interact with multiple molecular entities simultaneously and how these interactions influence entire biological networks[2].

At its core, network pharmacology constructs and analyzes drug–target–disease networks using advanced computational techniques and biological datasets. By mapping interactions across multiple biological layers, it allows researchers to identify key molecular hubs and critical signaling pathways that can be modulated for therapeutic purposes. This is particularly valuable for polygenic diseases where modulating a single target often fails to produce significant clinical benefits[3].

One of the major applications of network pharmacology lies in multi-target drug design. Instead of focusing on developing highly selective compounds, researchers now aim to design drugs capable of simultaneously modulating multiple targets or pathways involved in disease progression. This strategy mimics the body's natural biological regulation, where multiple processes operate in parallel and are interdependent. For instance, in cancer therapy, a drug that affects both tumor proliferation and angiogenesis pathways may achieve superior efficacy compared to single-target inhibitors[1].

Another significant contribution of network pharmacology is in drug repurposing, where existing drugs are systematically analyzed within disease-related networks to identify new therapeutic indications. Since these compounds already possess established safety profiles, drug repurposing can significantly reduce development time and costs. For example, computational network models have successfully revealed the potential of drugs approved for one disease to treat unrelated conditions by uncovering hidden connections between molecular pathways[4].

Network pharmacology also plays a critical role in target identification and validation. By integrating multi-omics datasets—such as genomics, transcriptomics, proteomics, and metabolomics—researchers can uncover previously unrecognized biological nodes that are central to disease mechanisms. Advanced algorithms and machine learning techniques allow these potential targets to be prioritized based on their network centrality and functional relevance[5].

Moreover, network pharmacology is increasingly being combined with artificial intelligence (AI), big data analytics, and personalized medicine. These integrations enable precise mapping of patient-specific molecular profiles, paving the way for individualized therapeutic strategies. Such approaches are particularly relevant in the era of precision medicine, where understanding inter-patient variability is essential for optimizing treatment outcomes[5].

Beyond synthetic drugs, network pharmacology has also revitalized research into natural products and traditional medicines, especially those involving multi-component formulations, such as Traditional Chinese Medicine (TCM) and Ayurveda. These therapies often exert therapeutic effects through synergistic modulation of multiple targets, making them ideal candidates for study through a network-based lens[6].

Despite its transformative potential, network pharmacology faces certain challenges. These include data quality issues, heterogeneity across biological datasets, and the complexity of accurately modeling biological systems. Furthermore, translating computational predictions into clinical success requires robust experimental validation and interdisciplinary collaboration among pharmacologists, bioinformaticians, systems biologists, and clinicians[6].

In summary, network pharmacology represents a paradigm shift from reductionist, single-target approaches toward holistic, multi-target therapeutic strategies. By leveraging advances in systems biology, computational modeling, and big data integration, it offers powerful tools to accelerate drug discovery, enable drug repurposing, and design safer, more effective treatments for complex diseases. As biomedical research continues to generate massive datasets, network pharmacology will play an increasingly central role in shaping the future of personalized and precision medicine[1].

Concept and Principles of Network Pharmacology

Network pharmacology is a new field that integrates systems biology, bioinformatics, and pharmacology to revolutionize contemporary drug discovery. It is a shift of paradigm from the classical "one drug, one target" concept to a "multi-target, multi-pathway" strategy, in which disease and therapeutic activities are analyzed in the context of complex biological networks instead of single molecular entities[7].

Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 3, Issue 2, Apr-Jun, 2026
Page No.: 31-44

Here, biological systems are perceived as networks of interconnected elements that include:

- Nodes: genes, proteins, metabolites, or drugs
- Edges: relationships or interactions between nodes

Diseases represent network perturbations due to dysfunction in several interacting pathways. Likewise, drugs are seen as external regulators that act on multiple targets to restore the homeostasis of biological systems[8].

Conventional drug discovery is bound to fail when treating multifactorial illnesses like cancer, diabetes, cardiovascular disease, and neurodegenerative diseases, where the effective treatment of a single molecule is rarely possible. Network pharmacology, on the other hand, adopts polypharmacology with an aim to develop or identify drugs that act to modulate multiple targets within disease-linked networks. This multi-target approach increases therapeutic efficacy, reduces drug resistance, and lowers undesirable effects due to compensatory responses[9].

One of the most important principles of cheminformatics and network pharmacology is the integration of multi-omics data, such as genomics, transcriptomics, proteomics, and metabolomics, to build overall interaction networks. These networks allow scientists to:

- Pinpoint hub genes or key regulatory nodes essential for disease progression.
- Define drug-target-pathway interactions for mechanism discovery.
- Make predictions regarding synergistic drug combinations for better therapy.
- Find drug repurposing opportunities by associating known drugs with novel disease pathways[10].

In addition, graph theory and computational modeling are utilized to assess network topology, including clusters, bottlenecks, and hub nodes that may act as best drug targets.

With the embrace of a systems-level view of disease, network pharmacology integrates comprehensively with the complexity of human biology. It also converges easily with artificial intelligence and precision medicine for the construction of personalized therapeutic strategies for specific molecular profiles[11].

In conclusion, network pharmacology offers a data-driven, multi-target, and systems-based strategy that improves drug discovery efficacy and efficiency, presenting promising therapeutic possibilities for the treatment of complicated diseases.

Tools and Databases in Network Pharmacology

Network pharmacology relies heavily on an array of computational software packages and biological databases that assist in the integration, analysis, and visualization of the intricate relationships among drugs, targets, diseases, and biological pathways. These resources provide the basis for the building of global drug-target-disease networks, investigation of therapeutic mechanisms, and discovery of new interventions. Among the commonly used databases, DrugBank contains comprehensive data on approved medications, investigational drugs, and their drug targets, and thus is a crucial resource for drug-target mapping and drug repurposing research[12]. In a similar vein, ChEMBL contains a carefully curated set of bioactive molecules with drug-like characteristics along with activity and binding affinity data, which are very valuable for computational modeling and virtual screening[13]. Another important database, BindingDB, is devoted entirely to experimental binding affinity data of drugs and protein targets, being highly useful for validation of computational predictions[14]. STRING provides rich information on protein-protein interactions (PPI) for the understanding of functional landscape of biological networks, allowing researchers to uncover disease mechanisms and drug action on complex signaling systems[15]. Moreover, STITCH combines experimental and predictive information to recognize chemical-protein interactions and is thus particularly useful for the identification of drugs with possible molecular mechanisms[16]. In the context of traditional medicine, the Traditional Chinese Medicine Systems Pharmacology Database (TCMSP) is extensively applied for the analysis of herbal formulations, their bioactive compounds, and related targets, thereby streamlining the incorporation of herbal-based therapies into contemporary drug discovery[17].

In complement to these databases are high-performance computational tools used by researchers to build, analyze, and visualize complex pharmacological networks. Cytoscape is one of the most widely used platforms for generating biological interaction networks and has several plugins available for pathway enrichment, identifying hub targets, and mechanistic

Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 3, Issue 2, Apr-Jun, 2026
Page No.: 31-44

investigations[18]. SwissTargetPrediction is another valuable tool that predicts probable molecular targets of compounds on the basis of chemical structure similarity to identify off-target effects and promote drug repurposing[19]. GeneMANIA facilitates functional prediction of gene-gene interactions by generating co-expression and co-functionality networks, which helps in elucidating disease pathways[20]. Likewise, NetworkAnalyst combines multi-omics data and supports sophisticated network analyses, biomarker discovery, and visualization of intricate biological relationships. Through the integration of these tools and databases, scientists can construct extensive drug-target-pathway networks, discover essential regulating nodes, forecast potential synergistic drug pairs, and confirm findings with experimental evidence. Therefore, these integrated computational tools are key to facilitating effective hypothesis generation, explanation of drug mechanisms, and the formulation of personalized therapeutic regimens in contemporary network pharmacology[21].

Network Pharmacology and Multi-Target Drug Discovery

Conventional drug discovery traditionally emphasized the development of very selective molecules that inhibit one molecular target, but this strategy is usually not successful for multifactorial diseases like cancer, diabetes, cardiovascular disease, autoimmune diseases, and neurodegenerative disorders, which are caused by dysregulation of several genes, proteins, and signaling pathways. Network pharmacology has revolutionized this paradigm by following a multi-target approach, also known as polypharmacology, which aims to design or discover drugs that can modulate multiple interconnected targets in a disease-related network simultaneously. Given the complexity of biological networks, this strategy increases therapeutic efficacy, decreases the risk of drug resistance, and diminishes adverse effects due to compensatory mechanisms when only one target is targeted. Network pharmacology uses drug-target-pathway interaction networks to screen hub proteins, regulatory bottlenecks, and function clusters in disease networks that can be modulated to induce larger therapeutic effects[22]. For instance, in oncology therapy, multi-target tyrosine kinase inhibitors like sorafenib target multiple signaling pathways, enhancing treatment efficacy against single-target agents. Likewise, in type 2 diabetes, drugs such as metformin not only affect glucose metabolism but also lipid regulation and inflammatory pathways, illustrating the need for multi-target modulation.[23]

Apart from single drugs affecting multiple targets, network pharmacology also allows for the design and optimization of drug combinations, where two or more agents act synergistically to modulate complementary pathways within disease networks. Computational methods calculate target overlap, pathway proximity, and synergy scores to forecast the best drug combinations. These approaches find significant utility in HIV, cancer, and COVID-19 management, where multi-drug therapy has become critical to establishing successful treatments. Multi-targeting not only enhances effectiveness, but it also creates opportunities for drug repurposing, wherein known drugs are mapped onto novel therapeutic uses based on their action across related pathways. This not only speeds up the drug discovery process but also lowers development costs. In addition, the combination of multi-omics data, AI-based modeling, and network simulations increases the accuracy of multi-target drug discovery, allowing researchers to design therapies on a patient-specific molecular basis. In general, network pharmacology is a comprehensive and data-centric strategy for drug development, outperforming conventional single-target approaches and opening the door to personalized medicine[24].

Role in Drug Repurposing

Drug repurposing, or drug repositioning, is a technique of finding new therapeutic applications for currently available drugs. It has become a strong strategy to decrease the cost, time, and risk involved in the conventional drug discovery process. The conventional drug discovery may take years and involve huge amounts of money, but the chances of clinical success are not high. Conversely, repurposing existing approved medications or investigational drugs presents a more effective option since their safety, pharmacokinetics, and toxicity profiles are already well-characterized. In this regard, network pharmacology comes into play by offering a rational platform to identify latent drug-disease relationships and investigate multi-target actions that traditional techniques may fail to observe[25].

Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 3, Issue 2, Apr-Jun, 2026
Page No.: 31-44

Network pharmacology combines systems biology, bioinformatics, and pharmacology to simulate the complex associations between drugs, genes, proteins, pathways, and diseases as interconnected networks instead of discrete objects. For drug repurposing, it facilitates scientists to evaluate the molecular interactions and biological pathways common in various diseases. For example, a compound initially designed for the treatment of a single disease can interact with targets or signaling pathways implicated in another disease. Network analysis reveals such common mechanisms by the identification of overlap molecular signatures, which allows researchers to make hypotheses about new therapeutic uses. In contrast to the conventional single-target methods, network pharmacology is aware of the complexity of disease as multi-gene, multi-pathway processes and utilizes the complexity to expand the therapeutic space of existing drugs[26].

A number of computational resources and publicly accessible databases facilitate network pharmacology-based drug repurposing. Resources such as DrugBank, STITCH, PharmGKB, and BindingDB offer comprehensive data on drug-target interactions, metabolic pathways, and disease associations. Integrating these with network-based modeling, scientists can map the interactions between drugs, targets, and diseases and predict new indications for approved drugs. For instance, network pharmacology has helped considerably in delineating potential drug uses in cancer, neurodegenerative diseases, cardiovascular illness, and re-emerging infectious illnesses. A notable example was in the case of COVID-19, where network pharmacology-based studies expedited the discovery of antiviral drugs by defining host-virus interaction networks and pinpointing drugs with the ability to modulate indispensable pathways of viral replication[27,28].

In addition, network pharmacology also allows for the detection of polypharmacological effects, wherein one drug acts on several molecular targets in concert. This is particularly important in sophisticated diseases such as cancer, diabetes, and autoimmune diseases, where influencing a single pathway alone proves to be inadequate. Through elucidation of these multi-target mechanisms, researchers can recycle drugs more efficiently and develop combinatorial therapies that achieve better therapeutic effects with fewer side effects[29].

In brief, network pharmacology has transformed drug repurposing from a "one drug-one target-one disease" model to a multi-target, multi-disease scheme. It utilizes big data, computational modeling, and network-based knowledge to reveal previously hidden therapeutic potential, thereby decreasing development times and expenses. As the biomedical information continues to expand exponentially, the combination of network pharmacology with other advanced computational tools such as artificial intelligence is expected to further enhance drug repurposing, rendering it a pillar in contemporary drug discovery and development[25].

Integration of Network Pharmacology with Artificial Intelligence and Machine Learning

Integration of network pharmacology with machine learning (ML) and artificial intelligence (AI) is transforming contemporary drug discovery and development by making it possible to effectively analyze huge biological data sets and enhance the accuracy of drug-target interaction prediction. Network pharmacology classically aims at elucidating intricate interactions between drugs, targets, genes, proteins, and pathways through a systems biology platform. Nevertheless, biological networks are complex, multidimensional, and highly dynamic in nature, and it is difficult to manually interpret these relationships. That is where AI and ML come into the picture by offering high-level computational models and algorithms that can analyze high-throughput biological data, identify latent patterns, and make predictions regarding possible therapeutic mechanisms with very high accuracy[30].

In drug discovery, predictive models based on AI examine large-scale omics data, clinical trial data, molecular structures, and pharmacological profiles to determine multi-target drugs and new therapeutic approaches. Support vector machines (SVMs), random forests (RFs), and deep learning neural networks are common machine learning algorithms to classify molecular properties, predict possible drug-protein interactions, and model disease-molecular pathway associations. For example, ML-based models coupled with network pharmacology can predict synergistic action of drug combinations by probing common signaling pathways and interaction networks. This allows for a dramatic speeding up of drug discovery by offering data-

Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 3, Issue 2, Apr-Jun, 2026
Page No.: 31-44

driven guide toward prioritizing compounds prior to experimental proof[31].

Moreover, AI improves target identification and ranking in network pharmacology through mapping and ranking the most impactful nodes of the biological networks. Deep learning models, which are learned from multi-omics data, are capable of predicting disease-linked targets and discovering previously unknown druggable nodes. This is especially helpful in the treatment of multifactorial diseases such as cancer, neurological disorders, and metabolic syndromes, where monotherapies are usually inadequate. By combining network pharmacology with ML, scientists can simulate disease-specific molecular networks to determine how disruptions at various nodes affect overall system behavior, allowing for personalized therapies tailored to the individual patient[32].

In addition, AI enables the integration of heterogeneous data sources, such as genomics, transcriptomics, proteomics, metabolomics, and clinical databases, into coherent network pharmacology platforms. This layer-by-layer integration of data enables scientists to construct more accurate disease models and reveal drug mechanisms with greater confidence. Natural language processing (NLP) techniques also supplement network pharmacology by extracting significant associations between drugs, targets, and diseases from vast biomedical literature to ensure that drug discovery is based on the most current scientific understanding[33].

In short, AI and ML integration with network pharmacology is a revolution in drug discovery and development. It improves efficiency, accuracy, and predictive capacity, enabling researchers to simulate complicated biological systems and develop multi-target interventions with unprecedented specificity[34]. Using computational intelligence, pharmaceutical research is shifting from trial-and-error to data-driven mechanism-based methods, the way forward to faster development of safer, more effective, and personalized medicines[35].

Application of Network Pharmacology in Personalized and Precision Medicine

Precision and personalized medicine seek to offer specific therapeutic interventions based on the individual features of every patient, such as their genetic profile, disease phenotype, way of life, and environment. Network pharmacology contributes significantly to this field by moving from the "one-size-fits-all" strategy to a systems-level understanding of the intricate biological networks behind diseases and drug response variability in individuals. Conventional drug discovery traditionally operates under the paradigm of "one drug, one target, one disease," which does not account for the multi-factorial nature of diseases and inter-individual variability. Network pharmacology, however, combines systems biology, bioinformatics, omics data, and computational modeling to build intricate interaction maps with genes, proteins, metabolites, and signaling pathways. This holistic view allows the detection of major molecular networks related to disease mechanisms and biological variations specific to a patient. Analyzing these networks, scientists are able to foresee how various individuals are likely to react to a given drug according to their individual molecular profiles, thereby allowing for an extremely individualized therapeutic approach[36].

Identifying patient-specific drug targets is one of the key uses of network pharmacology within precision medicine. Through integration of genomic, transcriptomic, proteomic, and metabolomic information, network pharmacology facilitates comprehension of the molecular causes of diseases at the individual level. For instance, two patients with the same clinical diagnosis may have disparate underlying molecular mechanisms to disease progression. Network-based models can identify different dysregulated pathways in each patient and propose different therapeutic interventions according to their unique biology. In the same way, drug response and side effects are significantly diverse among individuals because of genetic polymorphisms, epigenetic variations, and metabolic variations. Network pharmacology resources allow the incorporation of pharmacogenomic information into molecular interaction networks to predict drug effectiveness as well as adverse effects for every patient. This guarantees improved treatment results with negligible risks of toxicity[37].

In addition, network pharmacology facilitates the determination of combination therapy appropriate for a person's disease profile. In most multifactorial diseases like cancer, diabetes, and neurodegenerative disorders, several pathways are involved in the progression of disease. Single-target drugs cannot be successful because they get

Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 3, Issue 2, Apr-Jun, 2026
Page No.: 31-44

circumvented by the compensatory events in biological systems[38]. Network-based design explores the relationships between different targets and pathways and enables scientists to develop multi-target drug combinations tailored to a patient's individual molecular profile. Multi-target therapies are not just more successful, but also minimize the prospect of drug resistance, a key problem with personalized treatment schemes[39].

Furthermore, network pharmacology also facilitates biomarker discovery, which is central to precision medicine. Biomarkers allow for the stratification of patients according to disease subtype, prediction of drug response, and monitoring of therapeutic effect. By projecting disease-specific molecular signatures onto biological networks, researchers are able to detect pivotal biomarkers associated with successful or unsuccessful treatment. For example, in oncology, network-based biomarker detection has paved the way for personalized treatment plans based on tumor-specific mutation and signaling pathways. This approach ensures that patients receive therapies most likely to work for them, avoiding ineffective treatments and unnecessary exposure to side effects[40].

Additionally, network pharmacology enables the convergence of large data from electronic health records (EHRs), wearable sensors, and real-world clinical trials into precision medicine models. Merging these varied datasets with biological networks provides researchers with an enhanced understanding of heterogeneity of disease, variability in drug response, and patterns across populations. The integrated, holistic approach allows for dynamic, adaptive treatment schemes where therapeutics change in concert with a patient's disease development and shifting biological profile[41].

In summary, network pharmacology has a revolutionizing impact on personalized and precision medicine by connecting molecular-level understanding with patient-centric therapeutic approaches. By combining omics technologies, pharmacogenomics, and complex network modeling, it allows for exact identification of targets, biomarkers, and combination therapies in response to individual requirements. This approach not only enhances therapeutic efficacy and safety but is also a critical leap towards the future of truly personalized medicine. With further development of the field, the interplay between network pharmacology and artificial intelligence, machine learning, and big data analytics holds the potential to speed up the realization of precision medicine at the worldwide level.

Role in Traditional Medicine and Herbal Drug Discovery

Herbal medicines and traditional medicine have been in use for thousands of years across many cultures for the cure of numerous diseases. Notwithstanding their history of centuries and therapeutic appeal, their integration into contemporary drug development pipelines has been circumscribed by a number of issues such as the absence of scientific proof, poor understanding of their mechanism of action, as well as the intricacy of herbal preparations that consist of hundreds of bioactive molecules[42]. Network pharmacology offers a revolutionary platform to bridge such challenges by combining computational, biological, and pharmacological approaches to investigate how traditional herbal medicines achieve their therapeutic outcomes in a systematic and integrative way. In contrast to the traditional "one drug, one target" mode of operation, network pharmacology accepts the intrinsic complexity of herbal medicines and conforms to the multi-component, multi-target therapeutic regimens. This makes it a perfect method for investigating traditional medicine under a contemporary scientific framework[43].

One of the key strengths of network pharmacology in medicinal herbal drug discovery is that it can systematically recognize the active compounds of multifaceted herbal preparations and be able to forecast their biological targets. Utilizing sophisticated databases, cheminformatics methods, and systems biology techniques, scientists can be able to map out how phytochemicals interact with proteins, genes, and disease-related pathways. For instance, Ayurveda, Traditional Chinese Medicine (TCM), and Kampo are treasure houses of polyherbal preparations that act on several physiological systems at the same time. Network pharmacology enables scientists to dismantle these preparations by constructing compound-target-pathway-disease networks. Through this, it is feasible to find "key nodes" or hub molecules central to mediating therapeutic effects. This process not only validates traditional knowledge but also aids in the identification of lead compounds for novel drug development[43].

Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 3, Issue 2, Apr-Jun, 2026
Page No.: 31-44

Further, network pharmacology increases the insight into the synergistic effects in herbal medicines. Most herbal drugs depend on the combined action of many compounds instead of the activity of a single active compound. By modeling networks, scientists can see how more than one compound is interacting with overlapping and unique targets in diverse biological pathways, thereby revealing the mechanism behind synergy or antagonism. This streamlines the trial-and-error approach of conventional drug discovery and facilitates a more rational design of herbal therapeutics.

In addition, network pharmacology serves to bridge the gap between conventional medicine and precision medicine. Through the integration of omics data including genomics, transcriptomics, and metabolomics, it is feasible to define patient-specific targets and forecast personalized responses to herbal drugs. This is particularly pertinent in the treatment of polyfactorial and complicated diseases like cancer, diabetes, and neurodegenerative diseases, where herbal drugs have been known to offer multi-targeted treatments[44].

Moreover, databases such as TCMSP (Traditional Chinese Medicine Systems Pharmacology), TCMID, and HERB, along with molecular docking software and pathway analysis software, have completely transformed how researchers investigate herbal pharmacology. These tools enable researchers to systematically study herbal compounds, predict bioavailability, and evaluate their interaction with human proteins and disease pathways. For example, network pharmacology has efficiently led to the discovery of potential leads from herbals such as Curcuma longa (turmeric) and Withania somnifera (ashwagandha), providing mechanistic understanding of their anti-inflammatory, anti-cancer, and neuroprotective activities[45,46].

Overall, network pharmacology acts as a strong link between classical medicine and contemporary drug development by methodically revealing the molecular mechanism of herbal therapeutics. Its integrated strategy not only substantiates traditional practices but also speeds up the identification of innovative multi-targeting drugs with natural origins. Through the integration of ethnopharmacological information with advanced computational and systems biology approaches, network pharmacology opens up avenues to construct safe, efficient, and scientifically proved herbal medicines for meeting the demands of modern medicine[47].

Challenges in Network Pharmacology

Network pharmacology has become a revolutionary model in contemporary drug development and discovery, redirecting the conventional "one drug–one target" philosophy to a holistic, multi-target approach. Although its potential for expediting therapeutic findings is obvious, practicalization of network pharmacology is beset with many issues which limit its complete entry into drug research and clinical practice. These are the result of several factors, such as acquiring data, computational resource limitations, biological intricacies, validation problems, and regulatory constraints, all of which make it a challenging task to translate network-driven insights into clinically acceptable drugs[48].

The biggest challenge is with the availability, quality, and integration of data. Network pharmacology is based largely on large-scale biological data, such as genomics, proteomics, metabolomics, and transcriptomics, in addition to data from drug-target interactions, disease-gene associations, and clinical trials. These data are usually dispersed across various databases, and the methods used to collect them are disparate. The datasets frequently hold inconsistencies or gaps in information. Experimental conditions are different, there are errors in annotations, and there is no standardization, which complicates constructing accurate, reliable, and reproducible biological networks. In addition, the integration of multi-source heterogeneous datasets is of extreme technical challenge, in many cases demanding sophisticated computational methods and highly capable data harmonization infrastructures.

The other key challenge lies in the computational intensity of the analysis of large-scale biological networks. Since network pharmacology focuses on simulating intricate interactions among thousands of proteins, genes, metabolites, and drugs, the generated networks are extremely dynamic and multidimensional. Interpreting these networks correctly requires advanced computational methods, algorithms, and machine learning models able to process big data with minimal computational error. Yet, existing computational infrastructure and modeling methods are frequently not advanced enough to accommodate the complete complexity of

Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 3, Issue 2, Apr-Jun, 2026
Page No.: 31-44

biological systems when adding temporal dynamics, tissue-specific differences, and environmental factors[49].

The biological nature of disease also represents a primary hurdle. All diseases, especially chronic and complex multifactorial diseases such as cancer, neurodegenerative diseases, and metabolic syndromes, are characterized by complex molecular mechanisms and dynamic relationships among multiple pathways. Network pharmacology tries to chart such complex relationships, but our incomplete knowledge of biology constrains the accuracy of modeled networks. In most situations, predicted drug targets from computational predictions may not possess experimentally confirmed functions in disease processes, bringing doubts about choosing appropriate therapeutic approaches[50].

Another significant barrier is the experimental verification of computational predictions. Although network pharmacology offers strong predictions about potential drug targets, pathways, and multi-target drug combinations, it needs extensive laboratory and clinical testing to translate these data into preclinical and clinical applications. Experimental verification is costly, time-consuming, and labor-intensive, which often involves in vitro assays, animal models, and high-scale clinical trials. In addition, predictions by computational models and biological observations also disagree often, slowing drug development and weakening trust in network-based methods[51].

The convergence of traditional medicine and herbal drug discovery with network pharmacology adds complexity. Herbal products consist of hundreds of active compounds that target multiple sites at the same time, making it challenging to deconstruct their mechanisms of action with network strategies. Limited chemical characterization, the absence of a standardized database of herbs, and variation in the composition of herbs also create added complexity for research in this field[52].

Yet another key challenge is interpretability of network models. Though complex algorithms and machine learning methods can build predictive models, several such methods are "black boxes," where it is hard to interpret the mechanisms behind predictions. Explainability is very important for drug discovery, as regulatory bodies and doctors need to understand how discovered targets and drug leads connect with disease biology.

Lastly, the regulatory, ethical, and translational hurdles are still major barriers. The use of network pharmacology in clinical drug development requires new regulatory infrastructures to assess multi-target drugs and drug combinations efficiently. Furthermore, the absence of globally accepted standards for data sharing, model validation, and reporting poses obstacles to collaborative research and retards the innovation process[53].

In summary, although network pharmacology is envisioned to revolutionize drug development and discovery, addressing these challenges is critical for its successful application. Improvements in big data integration, machine learning, systems biology, and experimental validation methods will be decisive in bridging these gaps. An inter-disciplinary approach among computational scientists, biologists, clinicians, and regulators will also be crucial in ensuring that network pharmacology achieves its promise in designing safer, more efficient, and personalized therapeutics.

Future Perspectives

Network pharmacology is fast becoming a revolutionary strategy in contemporary drug discovery and development, connecting the past dots of single-target methods with the intricate biological nature of diseases. As science continues to evolve, its future outlook is very promising, with groundbreaking methodologies and solutions that can revolutionize the pharmaceutical sector, healthcare systems, and precision medicine. With the integration of leading-edge technologies, big data analysis, artificial intelligence (AI), machine learning (ML), and high-throughput omics platforms, network pharmacology is poised to define the future generation of therapeutics and reengineer the discovery, development, and application of drugs[54].

The integration of multi-omics data constitutes one of the most promising future directions of network pharmacology. As genomic, transcriptomic, proteomic, metabolomic, and epigenomic technologies get advanced, they give a holistic picture of biological systems at many molecular levels. Integrating these information into network pharmacology platforms allows scientists to develop very detailed disease-gene-protein-pathway networks. This panoramic overview makes possible the discovery of new targets for drugs, the prediction

Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 3, Issue 2, Apr-Jun, 2026
Page No.: 31-44

of possible off-target activities, and the elucidation of mechanisms of disease at unreached levels of detail. Additionally, combination of spatial transcriptomics and single-cell omics will also further optimize drug discovery pipelines by correlating cellular heterogeneity with tissue maps and driving drug responses at a microenvironmental level[55].

Yet another exciting future direction is the convergence between network pharmacology and artificial intelligence. As biological information becomes more complex and overwhelming, AI and ML algorithms can substantially augment predictive models in network pharmacology. Such technologies can analyze enormous amounts of multidimensional data, discover concealed patterns in molecular interaction networks, and make more accurate predictions about drug-target interactions. In addition, AI-based models are capable of virtual clinical trials, streamlining drug development pipelines, saving costs, and avoiding failures in downstream stages. The integration of AI, big data, and network pharmacology will therefore enable unprevisioned understanding of disease complexity and streamline drug design strategies[56].

Personalized and precision medicine will also stand to gain enormously from emerging developments in network pharmacology. By marrying patient-specific genomic, proteomic, and metabolomic profiles with network models, scientists can create customized treatment regimens that address multiple nodes and pathways associated with an individual's own unique disease signature. This type of strategy has the ability to enhance therapeutic effectiveness, reduce side effects, and break drug resistance frequently found in diseases such as cancer, autoimmune diseases, and neurodegenerative disorders. This patient-specific strategy may constitute a paradigm shift from "one-size-fits-all" medicine to network-guided individualized therapeutic modalities[30].

In addition, drug repurposing will continue to be a central interest in the future of network pharmacology. Through the mapping of known drugs onto large-scale disease-protein-pathway networks, scientists can effectively find novel therapeutic uses for previously approved drugs.

This method substantially streamlines development time, expense, and regulatory challenges and offers fast answers to looming health emergencies, including pandemics. When combined with AI, future network-based repurposing pipelines are able to rapidly shortlist good candidates and even forecast possible adverse effects prior to clinical trials.

Another promising avenue is the incorporation of classical medicine into contemporary drug discovery. Network pharmacology has the potential to deconstruct the action mechanisms of multi-ingredient herbal medicines employed in Ayurveda, Traditional Chinese Medicine (TCM), and other ancient medical systems. By overlaying phytochemicals with their interactions at several biological targets, scientists can scientifically prove traditional treatments and integrate them into evidence-based drug discovery pipelines. This may enable the creation of less hazardous, multi-targeted drugs that exploit the synergy present in natural products[43].

But the success of network pharmacology in the future will also rely on how to overcome current challenges, including data standardization, model validation, and scalability. For it to achieve its full potential, there is a need for international cooperation, open-access databases, and integrated computational frameworks that integrate heterogeneous biological data. Cloud computing, blockchain-based data sharing, and cross-disciplinary collaboration will be crucial in surmounting these challenges[57].

In summary, the future of network pharmacology is set to revolutionize contemporary drug discovery and medicine. By adopting systems-level strategies, combining AI and big data analytics, pushing the frontiers of personalized medicine, facilitating quick drug repurposing, and connecting ancient wisdom with contemporary science, network pharmacology will result in more effective, safer, and patient-friendly therapeutics. As the technology matures, it can drive faster innovation, lower costs, and create a future of precision medicine, where drugs are crafted on the basis of a detailed understanding of intricate biological systems instead of single molecular targets.

Conclusion

Network pharmacology is a revolutionary paradigm in contemporary drug discovery and development, breaking from the traditional "one drug, one target" era and focusing instead on a more integrated and systems-level approach. Combining pharmacology, systems biology, and bioinformatics, and

Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 3, Issue 2, Apr-Jun, 2026
Page No.: 31-44

computational science, network pharmacology enables researchers to decipher the complex relationships between drugs, targets, pathways, and diseases. In contrast to conventional drug development pipelines that frequently suffer from high attrition rates as a result of unexpected off-target effects or poor efficacy, network pharmacology allows a higher likelihood of analysing drug action in the context of the bigger biological picture. This markedly enhances the success rate of finding effective therapeutic agents and speeds up the process of moving scientific understanding into clinical utility.

One of the key advantages of network pharmacology is that it can help in multi-target drug discovery, which is an imperative feature when handling complex diseases like cancer, cardiovascular diseases, neurodegenerative diseases, and metabolic syndrome. Such diseases are generally controlled by complex molecular networks and not individual targets, thus it is imperative to design drugs that influence more than one node of the system. With the incorporation of omics data of large scale and computational resources, network pharmacology not only discovers potential multi-target agents but also predicts expected side effects, thus enhancing drug safety profiles.

Also, network pharmacology is crucial for drug repurposing through the unmasking of concealed relationships between approved drugs and new therapeutic applications. Through the modulation of drug-target-disease interactions, scientists can effectively reveal new therapeutic applications for approved drugs, with much less time, expense, and risk relative to conventional drug development. This feature has been especially useful in quick-response scenarios like the COVID-19 pandemic, where drug repurposing facilitated quicker therapeutic intervention.

In addition, the convergence of network pharmacology with new technologies such as artificial intelligence (AI) and machine learning (ML) is transforming the face of the pharmaceutical industry. AI-powered prediction models improve network-guided drug discovery by handling enormous databases, recognizing latent patterns, and increasing hypothesis generation. In the same vein, the combination of network pharmacology with precision and personalized medicine facilitates the customization of treatments using personal genomic and phenotypic information, allowing for more efficient and patient-specific therapies.

Despite its vast promise, network pharmacology is plagued by a number of challenges such as the quality and integration of disparate datasets, the necessity for reliable computational models, and experimental verification of predictions. Nonetheless, with ongoing progress in bioinformatics, AI, high-throughput tools, and big data analytics, these constraints are being overcome gradually.

In summary, network pharmacology is a paradigm shift towards contemporary drug discovery, providing a holistic and integrated strategy to study intricate biological systems and design safer, more effective, and targeted therapeutics. With the ongoing development of technological advancements, network pharmacology will likely play an increasingly pivotal role in determining the future of biomedical research and drug development, ultimately leading to enhanced patient care and unmet global medical needs.

Reference

1. Liu S, Yu YW. Network pharmacology: Changes the treatment mode of “one disease-one target” in cancer treatment. *World J Gastrointest Oncol*. 2025;17(1):101581. doi:10.4251/wjgo.v17.i1.101581
2. Polypharmacology. In: *Wikipedia*. 2025. Accessed September 1, 2025. https://en.wikipedia.org/w/index.php?title=Polypharmacology&oldid=1293521075
3. Csermely P, Korcsmaros T, Kiss HJM, London G, Nussinov R. Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review. *Pharmacol Ther*. 2013;138(3):333-408. doi:10.1016/j.pharmthera.2013.01.016
4. Rudrapal M, Paudel KR, Pangeni R. Editorial: Drug repurposing and polypharmacology: A synergistic approach in multi-target based drug discovery. *Front Pharmacol*. 2022;13. doi:10.3389/fphar.2022.1101007
5. He Z, Liu L, Han D, et al. POINT: a web-based platform for pharmacological investigation enhanced by multi-omics networks and knowledge graphs. *arXiv*. Preprint posted online March 10, 2025:arXiv:2503.07203. doi:10.48550/arXiv.2503.07203

Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 3, Issue 2, Apr-Jun, 2026
Page No.: 31-44

6. Chemogenomics. In: *Wikipedia*. 2025. Accessed September 1, 2025. https://en.wikipedia.org/w/index.php?title=Chemogenomics&oldid=1267337926
7. Kumari S, Verma A, Hasan S, et al. Network Pharmacology: A Systems-Based Paradigm-DrivenMulti-Target Drug Discovery &Development. *Eur J Cardiovasc Med*. 2025;15:659-664. doi:10.61336/ejcm/25-07-112
8. Liu Q, Zhang D, Wang B, et al. Network pharmacology: Advancing the application of large language models in traditional Chinese medicine research. *Sci Tradit Chin Med*. 2025;3(2):113. doi:10.1097/st9.0000000000000073
9. Tang J, Aittokallio T. Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles. *Curr Pharm Des*. 2014;20(1):23-36. doi:10.2174/13816128113199990470
10. Polypharmacology: promises and new drugs in 2022 | Pharmacological Reports. Accessed September 1, 2025. https://link.springer.com/article/10.1007/s43440-023-00501-4?utm_source=chatgpt.com
11. Network pharmacology: a bright guiding light on the way to explore the personalized precise medication of traditional Chinese medicine | Chinese Medicine | Full Text. Accessed September 1, 2025. https://cmjournal.biomedcentral.com/articles/10.1186/s13020-023-00853-2?utm_source=chatgpt.com
12. Wishart DS, Knox C, Guo AC, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. *Nucleic Acids Res*. 2008;36(Database issue):D901-906. doi:10.1093/nar/gkm958
13. Gaulton A, Bellis LJ, Bento AP, et al. ChEMBL: a large-scale bioactivity database for drug discovery. *Nucleic Acids Res*. 2012;40(Database issue):D1100-D1107. doi:10.1093/nar/gkr777
14. Info. Accessed September 1, 2025. https://www.bindingdb.org/rwd/bind/info.jsp?utm_source=chatgpt.com
15. Szklarczyk D, Nastou K, Koutrouli M, et al. The STRING database in 2025: protein networks with directionality of regulation. *Nucleic Acids Res*. 2025;53(D1):D730-D737. doi:10.1093/nar/gkae1113
16. STRING - Wikipedia. Accessed September 1, 2025. https://en.wikipedia.org/wiki/STRING?utm_source=chatgpt.com
17. Network Pharmacology-Based Approach Combined with Bioinformatic Analytics to Elucidate the Potential of Curcumol against Hepatocellular Carcinoma. Accessed September 1, 2025. https://www.mdpi.com/2073-4425/13/4/653?utm_source=chatgpt.com
18. Cytoscape. In: *Wikipedia*. 2025. Accessed September 1, 2025. https://en.wikipedia.org/w/index.php?title=Cytoscape&oldid=1307067500
19. Network Pharmacology-Based Approach Combined with Bioinformatic Analytics to Elucidate the Potential of Curcumol against Hepatocellular Carcinoma. Accessed September 1, 2025. https://www.mdpi.com/2073-4425/13/4/653?utm_source=chatgpt.com
20. Network Pharmacology-Based Approach Combined with Bioinformatic Analytics to Elucidate the Potential of Curcumol against Hepatocellular Carcinoma. Accessed September 1, 2025. https://www.mdpi.com/2073-4425/13/4/653?utm_source=chatgpt.com
21. Network pharmacology: a crucial approach in traditional Chinese medicine research | Chinese Medicine | Full Text. Accessed September 1, 2025. https://cmjournal.biomedcentral.com/articles/10.1186/s13020-024-01056-z?utm_source=chatgpt.com
22. Sorafenib. In: *Wikipedia*. 2025. Accessed September 1, 2025. https://en.wikipedia.org/w/index.php?title=Sorafenib&oldid=1304148694
23. The anti-inflammatory effect of metformin: The molecular targets. Accessed September 1, 2025. https://www.researchgate.net/publication/377975831_The_anti-inflammatory_effect_of_metformin_The_molecular_targets?utm_source=chatgpt.com
24. Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in

Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 3, Issue 2, Apr-Jun, 2026
Page No.: 31-44

triple-negative breast cancer | npj Systems Biology and Applications. Accessed September 1, 2025. https://www.nature.com/articles/s41540-019-0098-z?utm_source=chatgpt.com

25. Frontiers | How drug repurposing can advance drug discovery: challenges and opportunities. Accessed September 1, 2025. https://www.frontiersin.org/journals/drug-discovery/articles/10.3389/fddsv.2024.1460100/full?utm_source=chatgpt.com
26. Network medicine. In: *Wikipedia*. 2024. Accessed September 1, 2025. https://en.wikipedia.org/w/index.php?title=Network_medicine&oldid=1260380041
27. Recent advances in drug repositioning and rediscovery for different therapeutic activities utilizing updated technological approaches | Molecular Diversity. Accessed September 1, 2025. https://link.springer.com/article/10.1007/s11030-025-11248-w?utm_source=chatgpt.com
28. Li X, Yu J, Zhang Z, et al. Network bioinformatics analysis provides insight into drug repurposing for COVID-19. *Med Drug Discov*. 2021;10:100090. doi:10.1016/j.medidd.2021.100090
29. Drug repurposing for cancer therapy | Signal Transduction and Targeted Therapy. Accessed September 1, 2025. https://www.nature.com/articles/s41392-024-01808-1?utm_source=chatgpt.com
30. Joshi CP, Baldi A, Kumar N, Pradhan J. Harnessing network pharmacology in drug discovery: an integrated approach. *Naunyn Schmiedebergs Arch Pharmacol*. 2025;398(5):4689-4703. doi:10.1007/s00210-024-03625-3
31. Leveraging network pharmacology for drug discovery: Integrative approaches and emerging insights - ScienceDirect. Accessed September 1, 2025. https://www.sciencedirect.com/science/article/pii/S259009862500017X?utm_source=chatgpt.com
32. Zhang P, Zhang D, Zhou W, et al. Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine. *Brief Bioinform*. 2024;25(1):bbad518. doi:10.1093/bib/bbad518
33. Liu Q, Zhang D, Wang B, et al. Network pharmacology: Advancing the application of large language models in traditional Chinese medicine research. *Sci Tradit Chin Med*. 2025;3(2):113. doi:10.1097/st9.0000000000000073
34. Wang B, Zhang T, Liu Q, et al. Elucidating the role of artificial intelligence in drug development from the perspective of drug-target interactions. *J Pharm Anal*. 2025;15(3):101144. doi:10.1016/j.jpha.2024.101144
35. Machine Learning and Artificial Intelligence in Drug Repurposing—Challenges and Perspectives – Drug Repurposing Central. Accessed September 1, 2025. https://drugrepocentral.scienceopen.com/hosted-document?doi=10.58647%2FDRUGREPO.24.1.0004&utm_source=chatgpt.com
36. Turanli B, Karagoz K, Gulfidan G, Sinha R, Mardinoglu A, Arga KY. A Network-Based Cancer Drug Discovery: From Integrated Multi-Omics Approaches to Precision Medicine. *Curr Pharm Des*. 2018;24(32):3778-3790. doi:10.2174/1381612824666181106095959
37. Pharmacometabolomics. In: *Wikipedia*. 2023. Accessed September 1, 2025. https://en.wikipedia.org/w/index.php?title=Pharmacometabolomics&oldid=1188106203
38. Kumari S, Verma A, Hasan S, et al. Network Pharmacology: A Systems-Based Paradigm-DrivenMulti-Target Drug Discovery &Development. *Eur J Cardiovasc Med*. 2025;15:659-664. doi:10.61336/ejcm/25-07-112
39. Network pharmacology and AI in cancer research uncovering biomarkers and therapeutic targets for RALGDS mutations | Scientific Reports. Accessed September 1, 2025. https://www.nature.com/articles/s41598-025-91568-x?utm_source=chatgpt.com
40. Albert-László Barabási. In: *Wikipedia*. 2025. Accessed September 1, 2025. https://en.wikipedia.org/w/index.php?title=Albert-L%C3%A1szl%C3%B3_Barab%C3%A1si&oldid=1307586700
41. Nushi E, Popescu VB, Martin JAS, Ivanov S, Czeizler E, Petre I. Network modeling methods

Current Pharmaceutical Letters and Reviews (CPLR)
Website: https://cplr.in/
ISSN: 3049-222X
Vol. 3, Issue 2, Apr-Jun, 2026
Page No.: 31-44

for precision medicine. *arXiv*. Preprint posted online April 19, 2021:arXiv:2104.09206. doi:10.48550/arXiv.2104.09206

42. Frontiers | A critical assessment of Traditional Chinese Medicine databases as a source for drug discovery. Accessed September 1, 2025. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1303693/full?utm_source=chatgpt.com
43. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines | Journal of Cheminformatics | Full Text. Accessed September 1, 2025. https://jcheminf.biomedcentral.com/articles/10.1186/1758-2946-6-13?utm_source=chatgpt.com
44. Frontiers | Multi-level advances in databases related to systems pharmacology in traditional Chinese medicine: a 60-year review. Accessed September 1, 2025. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1289901/full?utm_source=chatgpt.com
45. Network pharmacological evaluation of Withania somnifera bioactive phytochemicals for identifying novel potential inhibitors against neurodegenerative disorder - PubMed. Accessed September 1, 2025. https://pubmed.ncbi.nlm.nih.gov/34278961/
46. Zhang Y, Chen R, Xu W. A network pharmacology-based analysis of Curcuma longa L.
47. Network Pharmacology and Bioinformatics Study of Six Medicinal Food Homologous Plants Against Colorectal Cancer. Accessed September 1, 2025. https://www.mdpi.com/1422-0067/26/3/930?utm_source=chatgpt.com
48. Thieme E-Journals - Planta Medica / Full Text. Accessed September 1, 2025. https://www.thieme-connect.com/products/ejournals/html/10.1055/a-2512-8928?utm_source=chatgpt.com
49. Frontiers | Challenges in phytotherapy research. Accessed September 1, 2025. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1199516/full?utm_source=chatgpt.com
50. Trends and Pitfalls in the Progress of Network Pharmacology Research on Natural Products - PMC. Accessed September 1, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12030339/?utm_source=chatgpt.com
51. Wang T, Chen S, Wang Y, et al. From In Silico to In Vitro: A Comprehensive Guide to Validating Bioinformatics Findings. *arXiv*. Preprint posted online January 24, 2025:arXiv:2502.03478. doi:10.48550/arXiv.2502.03478
52. Lin X, Dai L, Zhou Y, et al. Comprehensive evaluation of deep and graph learning on drug-drug interactions prediction. *Brief Bioinform*. 2023;24(4):bbad235. doi:10.1093/bib/bbad235
53. Ng JY, Kim M, Suri A. Exploration of facilitators and barriers to the regulatory frameworks of dietary and herbal supplements: a scoping review. *J Pharm Policy Pract*. 2022;15:55. doi:10.1186/s40545-022-00447-7
54. Network-based multi-omics integrative analysis methods in drug discovery: a systematic review | BioData Mining | Full Text. Accessed September 1, 2025. https://biodatamining.biomedcentral.com/articles/10.1186/s13040-025-00442-z?utm_source=chatgpt.com
55. Unlocking the power of spatial omics with AI - PMC. Accessed September 1, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12023348/?utm_source=chatgpt.com
56. He Z, Liu L, Han D, et al. POINT: a web-based platform for pharmacological investigation enhanced by multi-omics networks and knowledge graphs. *arXiv*. Preprint posted online March 10, 2025:arXiv:2503.07203. doi:10.48550/arXiv.2503.07203
57. Yang L, Wang H, Zhu Z, et al. Network Pharmacology-Driven Sustainability: AI and Multi-Omics Synergy for Drug Discovery in Traditional Chinese Medicine. *Pharmaceuticals*. 2025;18(7):1074. doi:10.3390/ph18071074

*****